Looking ahead, the integration of ILC-based therapies with current immunotherapeutic strategies, such as immune checkpoint inhibitors or metabolic modulators, holds considerable promise for enhancing treatment efficacy in cancer and immune-mediated diseases. The gene discussed is CCL27; the disease is cancer.